Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 96Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 10Recurrence 8Leukemia 8Neoplasm, Residual 6Hematologic Neoplasms 6Myeloproliferative Disorders 5Lymphoma, T-Cell, Peripheral 5Leukemia, Biphenotypic, Acute 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Monocytic, Acute 3Anemia, Refractory, with Excess of Blasts 3Neoplasm Metastasis 2Myeloid Malignancy 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2GATA2 Deficiency 2Breast Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Myeloid 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1

Interventions

asciminib 10Cyclophosphamide 9Mycophenolic Acid 7fludarabine 5Whole-Body Irradiation 5nilotinib 4fludarabine phosphate 4Stem Cell Transplantation 4Specimen Handling 4Dasatinib 4olverembatinib 3bosutinib 3Imatinib Mesylate 3Cyclosporine 3venetoclax 2ponatinib 2blinatumomab 2X-Rays 2Thiotepa 2Tacrolimus 2Sirolimus 2Melphalan 2Magnetic Resonance Spectroscopy 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporins 2Bone Marrow Transplantation 2Blood Component Removal 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Azacitidine × Clear all
NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

University of Chicago

Phase 1 Recruiting
18 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT06390306 2025-06-03

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Peking University People's Hospital

Recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡